A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
Part of paid clinical trials in Hoover, Alabama.
- Sponsor
- Incyte Corporation
- Study ID
- NCT03257644
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib phosphate cream — DRUGRuxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
Study Details
The purpose of this study is to evaluate the safety, tolerability and the pharmacokinetics (PK) of topical ruxolitinib cream applied to pediatric subjects (age ≥ 2 to 17 years) with atopic dermatitis (AD).
Key Dates
- Start date
- Sep 21, 2017
- Status verified
- Nov 2020
- Primary completion
- Oct 7, 2020
- Completion
- Oct 7, 2020
Study Design
- Enrollment
- 70 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1Ruxolitinib phosphate cream 0.5%.
- Experimental: Cohort 2Ruxolitinib phosphate cream 1.5%.
- Experimental: Cohort 3Ruxolitinib phosphate cream 0.75%.
- Experimental: Cohort 4Ruxolitinib phosphate cream 1.5%.
- Experimental: Cohort 5Ruxolitinib phosphate cream 0.75%.
- Experimental: Cohort 6Ruxolitinib phosphate cream 1.5%.
Primary Outcome Measure
Participants with treatment-emergent adverse events (TEAEs) [ Time Frame: Screening through 30-37 days after end of treatment, up to approximately 12 weeks. ]
Locations (23)
Find similar trials in Hoover, AL
By condition
By specialty
Related Studies
- Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic DermatitisPHASE4 · Recruiting · Northwestern University · Chicago, Illinois
- Ethnic Differences in Mechanisms of Action of DupilumabPHASE4 · Recruiting · University of Michigan · Ann Arbor, Michigan
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama